Kirin Company

Kirin Holdings and Kao Begin Joint Research On The Relationship Between Visceral Fat and Immunology

Retrieved on: 
Friday, November 11, 2022
University, Biotechnology, Education, Health, Pharmaceutical, Food, Beverage, Research, Infectious Diseases, Retail, Genetics, Science, Pittsburgh Food & Beverage Company, Kao Corporation, Degenerative disease, Fermentation, Research, Risk, CSV, Virus, Development, Health, Blood, Immunity, Wakayama Medical University, World Health Organization, Food, B cell, Conditional sentence, Incidence, Creating shared value, Obesity, PDC, Muscle, Kirin Holdings, Ageing, ESG, Kirin Company, Outline of health sciences, WHO, R, Biotechnology, Bacteria, Life, History, K25, Arteriosclerosis, Kao, View, Kirin, Association, NK, Immune system, World, Christian democracy, Goldwell, Pharmaceutical industry, Vaccine, Fine chemical, Attack, Jergens, Limited, Medication, Drink

Kirin Holdings and Kao will jointly conduct research to investigate the relationship between visceral fat and the activity of plasma cytoid dendritic cells*2 (pDCs), a key leader of the immune system, among others.

Key Points: 
  • Kirin Holdings and Kao will jointly conduct research to investigate the relationship between visceral fat and the activity of plasma cytoid dendritic cells*2 (pDCs), a key leader of the immune system, among others.
  • This research aims to elucidate the relationship between visceral fat and pDC activity by combining Kirin Holdings' more than 35 years of research capabilities in the field of immunology with Kao's research capabilities in improving visceral fat accumulation, which is at the root of lifestyle-related diseases.
  • Kao will collect data on lifestyle habits and the amount of visceral fat, while Kirin Holdings will collect data on the activity of dendritic cells, including pDCs, in the blood.
  • These data will be mutually shared, and the relationship between visceral fat and pDC activity will be jointly studied and analyzed.

OMRON Invests in Kirin Techno-System, Comprehensive Manufacturer of Inspection Machines

Retrieved on: 
Wednesday, October 26, 2022
Kirin Holdings, Creating shared value, Supply chain management, Time, KTS, Omron, Supply, Plastic, Combined, Drink, Senior, Automation, Food, Company, Industry, Health, Kirin Company, Environment, Automated business process, Engine department, Safety, Digital transformation, Digital, OMRON, Solution, Food engineering, Financial services, Recycling, Management, CSV, Limited, Kirin

KYOTO, Japan, Oct. 26, 2022 /PRNewswire/ -- OMRON Corporation (hereinafter "OMRON"), headquartered in Kyoto, and Kirin Brewery Company, Limited (hereinafter "Kirin Brewery"), a Tokyo-based group company of Kirin Holdings Company, Limited (hereinafter "Kirin"), also based in the Japanese capital, announced on October 18 that they have signed a Stock Purchase Agreement regarding OMRON's investment in Kirin Techno-System Company, Limited (hereinafter "KTS"), based in Kawasaki, to supply safe and secure beverages. OMRON's equity stake will be 60%, and Kirin Brewery's 40%.

Key Points: 
  • On the other hand, as the labor shortage in the manufacturing industry accelerates, automation of manual processes has become a management issue.
  • Through OMRON joining the investment in KTS, the two companies will jointly develop "Manufacturing DX (Digital Transformation)" solutions utilizing inspection data and contribute to the development of the food and beverage industry.
  • Both companies will co-create new value (solutions) by combining OMRON's advanced control technology with KTS' inspection technology.
  • Through this investment, OMRON will retain KTS' 'inspection machine,' which is becoming increasingly critical at production sites in the food and beverage industry.

 Kirin Holdings: Spoon and Bowl That Enhance the Salty Taste of Low-sodium Food by Approximately 1.5 Times*1 via Stimulation.

Retrieved on: 
Wednesday, September 7, 2022
Research, General Health, Consumer, Technology, Food, Beverage, University, Fitness & Nutrition, Education, Retail, Science, Other Consumer, Health, Food Tech, National Health, Ministry, Kirin Holdings, Technology, Food, Frustration, Development, Research, Ageing, Kirin Company, WHO, Life, Eating, Combined, Man, Medication, Meal, Meiji University, Department, School, Multimedia, Udon, Lists of companies, CLT, Kirin, Biotechnology, CSV, National Health and Nutrition Examination Survey, List of health departments and ministries, Drinking, World, Outline of health sciences, Fermentation, Food market, Woman, Functional electrical stimulation, Taste, World Health Organization, Television, Dietary supplement, Public relations, Salt, Medical device, Convenience food, Cutlery, Candy, Limited, Health, Drink

Through this device, we aim to realize a society in which people can improve their lifestyle in a delicious way.

Key Points: 
  • Through this device, we aim to realize a society in which people can improve their lifestyle in a delicious way.
  • After making your selection, use the spoon in the same way as a normal spoon.
  • A weak electric current is passed through the food to produce the effect, from the tip of the spoon.
  • Change value of evaluation regarding saltiness intensity in a sample that imitates ordinary food and a sample with 30% less salt.

Kirin Holdings’ Long-term GHG Reduction Target Was Approved by the Science Based Targets*1 Initiative Based on Science-based Net-zero Targets

Retrieved on: 
Friday, August 5, 2022
Sustainability, Environment, Environmental Policy, Recycling, Environmental Issues, Climate Change, Food, Beverage, Retail, Zero, CSV, CDP, Climate change, United Nations Global Compact, WRI, Kirin Company, Paris Agreement, Silent Scope 3, World Resources Institute, Engineering, WWF, Food, PET, Kirin, Kirin Holdings, World Wide Fund for Nature, Lists of companies, GHG, IPCC, Climate, Renewable energy, Limited

In order to achieve that common global long-term goal, many companies in the world have set "2050 Net Zero" targets.

Key Points: 
  • In order to achieve that common global long-term goal, many companies in the world have set "2050 Net Zero" targets.
  • In response to this flurry of net-zero targets, the SBT Initiative developed the "Net Zero Standard" in October 2021.
  • Science Based Targets: Greenhouse gas reduction targets based on scientific evidence.
  • A state in which anthropogenic GHG emissions and removals are balanced and GHG emissions to the atmosphere are net zero.

Dr. Eri Nakazaki of the Kirin Central Research Institute Wins JSBBA Award for Her Work Developing a Health Food Ingredient to Support Memory

Retrieved on: 
Wednesday, June 1, 2022
Woman, Science, Interview, Kirin Company, Research, Government budget balance, Man, Marketing, AAMI, MBA, Kyowa Hakko Kirin, GRAS, Hope, Japan Society for Bioscience, Biotechnology, and Agrochemistry, Functional food, Randomness, Kirin Holdings, Memory, Growth, RD, Health, Kyōwa, Dementia, NEW, Attention, Fermentation, Dietary supplement, Pharmaceutical industry, Biotechnology, Limited, Citicoline

NEW YORK, June 1, 2022 /PRNewswire-PRWeb/ -- Leading international health ingredient manufacturer Kyowa Hakko U.S.A., Inc. and its parent company, Kirin Holdings, announced that Dr. Eri Nakazaki of the Kirin Central Research Institute was one of the winners of the 2022 JSBBA Award for Women Corporate Researchers for her work in developing Cognizin® Citicoline, Kyowa Hakko's patented, ultra-pure, high-quality form of citicoline that is clinically studied to support brain health, mental energy, focus, and attention.

Key Points: 
  • This is the second time a member of the Kirin Central Research Institute has won the award, the first winner having been announced in 2020.
  • Citicoline is a naturally occurring brain nutrient found in the body and is especially vital to brain health.
  • The study proves that the product can be used as a functional health food ingredient to support memory.
  • Our mission is to contribute to improving the health of people through science as we discover more health benefits of food ingredients."

Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s

Retrieved on: 
Friday, July 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Managed care, Kyowa Hakko Kirin, Companies, Kirin, Istradefylline, HiSilicon, Economy of Japan, Drugs, Kirin Company, istradefylline, Parkinson’s and ‘OFF’ episodes, Kyowa Kirin International in neurology, Kyowa Kirin, ISTRADEFYLLINE, PARKINSON’S AND ‘OFF’ EPISODES, KYOWA KIRIN INTERNATIONAL IN NEUROLOGY, KYOWA KIRIN

Kyowa Kirin International remain committed to istradefylline and people living with Parkinsons and are currently reviewing the options available, which may include re-examination.

Key Points: 
  • Kyowa Kirin International remain committed to istradefylline and people living with Parkinsons and are currently reviewing the options available, which may include re-examination.
  • First of all, I would like to appreciate those who have contributed to the development of istradefylline.
  • You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/ .
  • Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd.

Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory

Retrieved on: 
Wednesday, March 31, 2021
Kyowa Hakko Kirin, Companies, Kirin, HiSilicon, Economy of Japan, Japanese culture, Kirin Holdings, Kirin Company

BEDMINSTER, N.J., March 31, 2021 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key milestone in its North American Business Integration (NABI) initiative; specifically, the merger of its Kyowa Kirin Research and Kyowa Kirin Development companies into Kyowa Kirin, Inc.

Key Points: 
  • BEDMINSTER, N.J., March 31, 2021 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key milestone in its North American Business Integration (NABI) initiative; specifically, the merger of its Kyowa Kirin Research and Kyowa Kirin Development companies into Kyowa Kirin, Inc.
  • Kyowa Kirin Canada, Inc. and BioWa, Inc., both maintain their current structure as subsidiaries of Kyowa Kirin, Inc. and Kyowa Kirin USA Holdings, Inc. respectively.
  • The organizational changes we are making through NABI will help Kyowa Kirin North America deliver the full value of these opportunities," says Gary Zieziula, President, Kyowa Kirin North America.
  • You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.

Kyowa Hakko Bio Establishes New Facility in Thailand to Supply Human Milk Oligosaccharides Worldwide

Retrieved on: 
Wednesday, November 4, 2020
Companies, Branches of biology, Kyowa Hakko Kirin, Kirin Holdings, Kirin Company, Economy of Japan, Kirin, Human milk oligosaccharide

TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.

Key Points: 
  • TOKYO, Nov. 4, 2020 /PRNewswire-PRWeb/ --KYOWA HAKKO BIO CO. LTD. (Kyowa Hakko Bio), a subsidiary of Kirin Holdings Company, Limited (Kirin Holdings), has announced that it will establish a new facility to manufacture human milk oligosaccharides (HMOs) in Thailand.
  • Kyowa Hakko Bio decided on the move with expectations of a future increase in global demand for HMOs.
  • The new facility is to be established at Kyowa Hakko Bio's subsidiary Thai Kyowa Biotechnologies Co., Ltd. (Thai Kyowa) in Rayong Province, Thailand.
  • Kyowa Hakko Bio will be able to secure a competitive advantage through its strain development and manufacturing process development capabilities.

MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401

Retrieved on: 
Tuesday, April 14, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Kirin, Companies, Kirin Company, the Global License, Development and Commercialization Agreement, ME-401, MEI Pharma, Kyowa Kirin

MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.

Key Points: 
  • MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.
  • "I am delighted to expand our agreement with MEI Pharma for the development and commercialization of ME-401 all over the world," said Tomohiro Sudo, Executive Officer, Director of Strategic Product Planning Department for Kyowa Kirin.
  • If approved by FDA in the U.S., MEI and Kyowa Kirin will co-promote ME-401, with MEI booking all revenue from sales.
  • Outside the U.S., Kyowa Kirin will have exclusive commercialization rights, lead commercialization and book all revenues from sales of ME-401.

MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401

Retrieved on: 
Tuesday, April 14, 2020
Kirin, Companies, Kirin Company

MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.

Key Points: 
  • MEI and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S., with MEI booking all revenue from U.S. sales.
  • "I am delighted to expand our agreement with MEI Pharma for the development and commercialization of ME-401 all over the world," said Tomohiro Sudo, Executive Officer, Director of Strategic Product Planning Department for Kyowa Kirin.
  • If approved by FDA in the U.S., MEI and Kyowa Kirin will co-promote ME-401, with MEI booking all revenue from sales.
  • Outside the U.S., Kyowa Kirin will have exclusive commercialization rights, lead commercialization and book all revenues from sales of ME-401.